Search
Fibrobiologics Inc
FBLGAdd to Watchlist
1.050USD
-0.030-2.78%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
3.69MMarket Cap
LossP/E TTM
More Details of Fibrobiologics Inc Company
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Fibrobiologics Inc Info
Ticker SymbolFBLG
Company nameFibrobiologics Inc
IPO dateJan 31, 2024
CEOO'Heeron (Pete)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 31
Address455 E. Medical Center Blvd
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77598
Phone12816715150
Websitehttps://fibrobiologics.com/
Ticker SymbolFBLG
IPO dateJan 31, 2024
CEOO'Heeron (Pete)
Company Executives of Fibrobiologics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
9.00K
--
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
3.06K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
375.00
--
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Golden Knight Inc LP
6.48%
O'Heeron (Peter)
5.72%
Armistice Capital LLC
4.98%
The Lind Partners, LLC
3.03%
Vanguard Capital Management, LLC
1.30%
Other
78.49%
Shareholders
Shareholders
Proportion
Golden Knight Inc LP
6.48%
O'Heeron (Peter)
5.72%
Armistice Capital LLC
4.98%
The Lind Partners, LLC
3.03%
Vanguard Capital Management, LLC
1.30%
Other
78.49%
Shareholder Types
Shareholders
Proportion
Corporation
6.48%
Individual Investor
6.14%
Investment Advisor
5.99%
Hedge Fund
5.53%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.21%
Venture Capital
0.04%
Other
74.14%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
139
258.88K
4.97%
-83.81K
2025Q4
125
5.16M
16.27%
--
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Golden Knight Inc LP
337.49K
9.61%
+53.75K
+18.94%
Mar 13, 2026
O'Heeron (Peter)
297.91K
8.48%
+2.58K
+0.87%
Mar 13, 2026
BlackRock Institutional Trust Company, N.A.
23.87K
0.68%
+2.13K
+9.81%
Dec 31, 2025
Geode Capital Management, L.L.C.
17.44K
0.5%
+2.99K
+20.70%
Dec 31, 2025
Cascade Financial Partners, LLC
15.73K
0.45%
+825.00
+5.54%
Dec 31, 2025
Millennium Management LLC
14.43K
0.41%
-7.88K
-35.34%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 25, 2026
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Mar 25, 2026
Merger
20→1
